CompletedNot Applicable

Prehabilitation Plus ERAS in Gastric Cancer Surgery

China136 participantsStarted 2024-12-05

Plain-language summary

This study aims to evaluate the impact of pre-habilitation combined with Enhanced Recovery After Surgery (ERAS) versus ERAS perioperative management alone on clinical outcomes in patients with gastric cancer undergoing neoadjuvant chemotherapy and laparoscopic (robotic) gastrectomy. The study is a single-center, randomized controlled trial involving patients aged 18-75 years. Participants will be randomly assigned to either a pre-habilitation program plus ERAS or ERAS alone. The primary outcome is the incidence of postoperative complications within 30 days. Secondary outcomes include pathological data, surgical outcomes, patient-reported outcomes, and long-term survival rates.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age:18-75 years * ECOG:0-2 * ASA:I-III * Histologically confirmed gastric adenocarcinoma (cT3-4aN+M0) * Fit for radical surgery after MDT * Negative pregnancy test within one month * Non-pregnant or non-lactating Exclusion Criteria: * Severe cardiac (LVEF\<30% or NYHA IV) * Severe hepatic or renal dysfunction (Child-Pugh ≥10; CrCl\<25 ml/min) * Recent cerebrovascular events * Concomitant tumors requiring surgery * Emergency surgery for tumor complications, * Severe infections

What they're measuring

Incidence of Postoperative Complications

Timeframe: Postoperative 30-day

Trial details

NCT IDNCT07328633

SponsorThe Affiliated Hospital of Qingdao University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-30

View on ClinicalTrials.gov More Gastric Cancer (GC) trials